TQC 2938
Alternative Names: TQC-2938Latest Information Update: 28 Aug 2026
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Interleukin 1 receptor-like 1 protein antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Allergic rhinitis; Chronic obstructive pulmonary disease
- No development reported Asthma
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for phase-I development in Asthma(In volunteers) in China (IV, Injection)
- 28 Aug 2026 No recent reports of development identified for phase-I development in Asthma(In volunteers) in China (SC, Injection)
- 16 Jun 2026 Efficacy and adverse event data from phase II trial in Allergic-rhinitis released by Sino Biopharmaceutical